Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pin.12226 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma.
Mod Pathol
January 2025
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA. Electronic address:
Histologic features, including architectural patterns, cytologic features, and 2021 World Health Organization nuclear grade have been shown to have prognostic significance in epithelioid diffuse pleural mesothelioma (DPM). Biphasic and sarcomatoid DPM, regardless of morphology, have worse outcomes. These prognostic findings are well-established but correlation of architectural patterns, cytologic features, and nuclear grade with genetic alterations has not been well studied.
View Article and Find Full Text PDFIntroduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor (ICI), for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM) based on the MERIT trial, a phase II study of 34 cases. However, concerns regarding limited evidence persist.
Methods: We retrospectively analyzed 83 patients with previously treated, unresectable, advanced, or recurrent malignant pleural mesothelioma (MPM) treated with nivolumab from August 2018 to May 2022.
Primary tumor characteristics and immunohistochemical profile of renal cell carcinoma in serous fluid cytology.
J Am Soc Cytopathol
November 2024
Cytopathology Center of Excellence, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Introduction: Renal cell carcinoma (RCC) involves serosal surfaces in 2%-3% of cases, and thus few papers describe serous fluid cytology (SFC) involvement by RCC. This diagnosis is challenging, given its rarity, nondescript cytomorphologic features and infrequent expression of widely used epithelial markers MOC31 and BerEP4. We describe our institutional experience with RCC in SFC specimens.
View Article and Find Full Text PDFChallenges in the Diagnosis and Management of Renal Cell Carcinoma With Sarcomatoid Differentiation: A Case Report.
Cureus
November 2024
Department of Internal Medicine, Merit Health Wesley, Hattiesburg, USA.
Metastatic sarcomatoid renal cell carcinoma (sRCC) is a significant therapeutic and diagnostic challenge due to its rarity and aggressiveness, which contribute to its poor prognosis. This case report presents the case of a 47-year-old Caucasian man with shortness of breath and right-sided abdominal pain. History revealed an extensive smoking history, a left renal mass diagnosed two months ago with inconclusive results, and an enlarged mass on computed tomography (CT) scan one week ago in an emergency department (ED) visit that showed signs consistent with metastatic disease.
View Article and Find Full Text PDFReal-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
JTO Clin Res Rep
December 2024
Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, Switzerland.
Article Synopsis
- A study on the combination of ipilimumab (ipi) and nivolumab (nivo) for treating malignant pleural mesothelioma (MPM) in Switzerland revealed real-world survival and safety data, confirming its status as a standard-of-care after positive clinical trial results (CheckMate-743).
- Among the 109 patients treated from November 2017 to March 2023, the objective response rate to ipi-nivo was 21% for first-line treatment and 15% for second or further-line treatments, with median overall survival being 12.6 months for first-line and 6.9 months for second-line.
- The treatment was generally well-t
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!